FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176223162> ?p ?o ?g. }

• W3176223162 abstract "Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK+ non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second-generation ALK TKI have demonstrated superiority compared to the first-generation compound crizotinib and are meanwhile standard first-line treatment. However, clinical courses of individual patients vary widely, with secondary development of drug resistance and intracranial progression remaining important problems. While these limitations highlight the need for better disease monitoring and additional therapeutic tools, molecular tumor features are increasingly recognized as crucial determinants of clinical outcome. This trial aims to optimize management of ALK+ NSCLC by analyzing the efficacy of second-generation ALK inhibitors in conjunction with deep longitudinal phenotyping across two treatment lines.In this exploratory prospective phase II clinical trial, newly diagnosed ALK+ NSCLC patients will be randomized into two treatment arms, stratified by presence of brain metastases and ECOG performance status: brigatinib (experimental arm) vs. any other approved second-generation ALK TKI. Tumor tissue and blood samples will be collected for biomarker analysis at the beginning and throughout the study period to investigate baseline molecular tumor properties and analyze the development of acquired drug resistance. In addition, participating investigators and patients will have the possibility of fast-track molecular tumor and ctDNA profiling at the time of disease progression using state-of-the-art next-generation sequencing (NGS), in order to support decisions regarding next-line therapy.Besides supporting therapeutic decisions for enrolled patients, the ABP trial primarily aims to deepen the understanding of the underlying biology and facilitate development of a framework for individualized management of ALK+ NSCLC according to molecular features. Patients with low molecular risk and the perspective of a chronic disease will be distinguished from high-risk cases, molecular properties of which will be utilized to elaborate improved methods of non-invasive monitoring and novel preclinical models in order to advance therapeutic strategies.Clinicaltrials.gov , NCT04318938. Registered March 182,020, https://www.clinicaltrials.gov/ct2/show/NCT04318938 Eudra-CT, 2019-001828-36. Registered September 302,019, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001828-36." @default.
• W3176223162 created "2021-07-05" @default.
• W3176223162 creator A5013804417 @default.
• W3176223162 creator A5014427777 @default.
• W3176223162 creator A5018231423 @default.
• W3176223162 creator A5021528092 @default.
• W3176223162 creator A5025473299 @default.
• W3176223162 creator A5026607584 @default.
• W3176223162 creator A5052292725 @default.
• W3176223162 creator A5053206032 @default.
• W3176223162 creator A5072714653 @default.
• W3176223162 creator A5084519979 @default.
• W3176223162 date "2021-06-28" @default.
• W3176223162 modified "2023-10-14" @default.
• W3176223162 title "Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial" @default.
• W3176223162 cites W1525117983 @default.
• W3176223162 cites W1970277362 @default.
• W3176223162 cites W2000397789 @default.
• W3176223162 cites W2019607817 @default.
• W3176223162 cites W2039316040 @default.
• W3176223162 cites W2106787323 @default.
• W3176223162 cites W2106915761 @default.
• W3176223162 cites W2236017705 @default.
• W3176223162 cites W2482427906 @default.
• W3176223162 cites W2564366019 @default.
• W3176223162 cites W2624310346 @default.
• W3176223162 cites W2683488101 @default.
• W3176223162 cites W2767874086 @default.
• W3176223162 cites W2789601608 @default.
• W3176223162 cites W2794472180 @default.
• W3176223162 cites W2803802743 @default.
• W3176223162 cites W2804314915 @default.
• W3176223162 cites W2889170871 @default.
• W3176223162 cites W2892935819 @default.
• W3176223162 cites W2894476389 @default.
• W3176223162 cites W2910636472 @default.
• W3176223162 cites W2910725040 @default.
• W3176223162 cites W2925139051 @default.
• W3176223162 cites W2942955398 @default.
• W3176223162 cites W2944904335 @default.
• W3176223162 cites W2988002600 @default.
• W3176223162 cites W2990041408 @default.
• W3176223162 cites W2999417355 @default.
• W3176223162 cites W3011331060 @default.
• W3176223162 cites W3022131485 @default.
• W3176223162 cites W3032353482 @default.
• W3176223162 cites W3048441995 @default.
• W3176223162 cites W3088144056 @default.
• W3176223162 cites W3095012915 @default.
• W3176223162 cites W4210992155 @default.
• W3176223162 doi "https://doi.org/10.1186/s12885-021-08460-w" @default.
• W3176223162 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8240323" @default.
• W3176223162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34182952" @default.
• W3176223162 hasPublicationYear "2021" @default.
• W3176223162 type Work @default.
• W3176223162 sameAs 3176223162 @default.
• W3176223162 citedByCount "3" @default.
• W3176223162 countsByYear W31762231622022 @default.
• W3176223162 countsByYear W31762231622023 @default.
• W3176223162 crossrefType "journal-article" @default.
• W3176223162 hasAuthorship W3176223162A5013804417 @default.
• W3176223162 hasAuthorship W3176223162A5014427777 @default.
• W3176223162 hasAuthorship W3176223162A5018231423 @default.
• W3176223162 hasAuthorship W3176223162A5021528092 @default.
• W3176223162 hasAuthorship W3176223162A5025473299 @default.
• W3176223162 hasAuthorship W3176223162A5026607584 @default.
• W3176223162 hasAuthorship W3176223162A5052292725 @default.
• W3176223162 hasAuthorship W3176223162A5053206032 @default.
• W3176223162 hasAuthorship W3176223162A5072714653 @default.
• W3176223162 hasAuthorship W3176223162A5084519979 @default.
• W3176223162 hasBestOaLocation W31762231621 @default.
• W3176223162 hasConcept C117643217 @default.
• W3176223162 hasConcept C126322002 @default.
• W3176223162 hasConcept C143998085 @default.
• W3176223162 hasConcept C2776232967 @default.
• W3176223162 hasConcept C2776256026 @default.
• W3176223162 hasConcept C2778347629 @default.
• W3176223162 hasConcept C2779422266 @default.
• W3176223162 hasConcept C2780140570 @default.
• W3176223162 hasConcept C535046627 @default.
• W3176223162 hasConcept C71924100 @default.
• W3176223162 hasConceptScore W3176223162C117643217 @default.
• W3176223162 hasConceptScore W3176223162C126322002 @default.
• W3176223162 hasConceptScore W3176223162C143998085 @default.
• W3176223162 hasConceptScore W3176223162C2776232967 @default.
• W3176223162 hasConceptScore W3176223162C2776256026 @default.
• W3176223162 hasConceptScore W3176223162C2778347629 @default.
• W3176223162 hasConceptScore W3176223162C2779422266 @default.
• W3176223162 hasConceptScore W3176223162C2780140570 @default.
• W3176223162 hasConceptScore W3176223162C535046627 @default.
• W3176223162 hasConceptScore W3176223162C71924100 @default.
• W3176223162 hasFunder F4320330130 @default.
• W3176223162 hasFunder F4320333265 @default.
• W3176223162 hasIssue "1" @default.
• W3176223162 hasLocation W31762231621 @default.
• W3176223162 hasLocation W31762231622 @default.
• W3176223162 hasLocation W31762231623 @default.
• W3176223162 hasOpenAccess W3176223162 @default.
• W3176223162 hasPrimaryLocation W31762231621 @default.
• W3176223162 hasRelatedWork W1957032760 @default.

• next